/  print page

References

EPO has currently customers from more than 125 scientific institutes, biotech and pharmaceutical companies worldwide.

Selected publications

• Wulf-Goldenberg A, et al. (2008). Cytokine-pretreatment of CD34+ cord blood stem cells in vitro reduces long-term cell engraftment in NOD/SCID mice. Eur J Cell Biol 87:69-80.

• Behrens D, et al. (2007). Loss of Tumorigenicity
  of stably ERβ-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 274:19-29.

• Behrens D, et al. (2007). The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts. Targeted Oncology 2:135-144.

• Zeisig R, et al. (2007). Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys 459:98-106.

• Fichtner I, et al. (2006). Antitumor activity of titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs 17:333-336.

• Einsiedel HG, et al. (2006). Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 20:1435-1436.

• Schanzer JM, et al. (2006). Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. J Immunother 29:477-488.

• Shalapour S, et al. (2006). The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12:5526-5532.

• Becker M, et al. (2005). Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Thera 4:151-168.

• Schlereth et al. (2005). Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65:2882-2889.

• Fichtner I, et al. (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298-307.

• Keil C, et al. (2005) Effect of surface modified liposomes on the aggregation of platelets and tumor cells. Thromb Haemost 94:404-411.

• Zeisig R, et al. (2004). Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin mediated tumor cell adhesion in vitro. Biochim Biophys Acta 1660:31-40.

• Fichtner I, et al. (2004). In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 40:845-851.

• Zeisig R, et al. (2004). Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro. Breast Cancer Res Treat 87:245-254.

• Fichtner I, et al. (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298-307.

• Fichtner I, et al. (2004). In vivo models for endocrine tumors: Special considerations. Eur J Cancer 40:845-851.

• Fichtner I, et al. (2003). Animal experiments - an essential component for the development of liposomal anticancer agents. J Liposome Res 13: 9-15.

• Zeisig R, et al. (2003). Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy. Cancer Gene Therapy 10:302-311.

• Fichtner I, et al. (2003). Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias - correlation to the expression of multidrug resistance proteins. Anticancer Res 23: 2657-2664.

• Dreier T, et al. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct1. J Immunol 170: 4397-4402.

• Becker M, et al. (2002). Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Brit J Cancer 87:1328-1335.

• Naundorf H, et al. (2000). Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Brit J Cancer 82: 1844-1850.

• Goan SR, et al. (2000). Donor stromal cells from human blood engraft in NOD/SCID mice. Blood 96: 3971-3978.

Top